The Health Bureau (SSM) announced in a statement last night that it will start the administration of Germany’s BioNTech mRNA jabs targeting the Omicron JN.1 subvariants tomorrow.
BioNTech mRNA vaccine against COVID-19 is administered to all those aged at least six months.
The statement noted that Omicron JN.1 are the currently prevalent subvariants, adding that the Macau Health Bureau has purchased BioNTech mRNA jabs targeting the JN.1 subvariants in compliance with the World Health Organisation’s (WHO) guidelines.
Appointments for a jab can be made from 10 a.m. today on https://eservice.ssm.gov.mo/covidvacbook
The statement also urged high-risk individuals to receive a JN.1 jab, such as senior citizens, those with chronic diseases, those with weakened immune systems, pregnant women, and frontline health workers.
The statement pointed out that the jabs are free of charge for all local residents, non-resident workers (NRWs), prison inmates, and non-locals studying in Macau.
The statement noted that all other non-locals holding a permit to stay in Macau have to pay 250 patacas per jab.
According to the statement, the Health Bureau recommends that everyone aged five or over receive a BioNTech mRNA JN.1 jab, regardless of whether they have previously been vaccinated against COVID-19.
According to the statement, the bureau recommends that those aged from six months through four years receive three JN.1 jabs if they have never received any COVID-19 jabs.
Those in this age group who have previously received one non-JN.1 jab are recommended to receive two JN.1 jabs, the statement said.
According to the statement, those in this age group who have previously received two or more non-JN.1 jabs are recommended to receive one JN.1 jab.
The statement underlined that the new JN.1 jabs can provide better protection against COVID-19 than the current jabs for the Omicron XBB subvariants.
BioNTech is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
This poster in Chinese released by the Health Bureau (SSM) last night promotes its new COVID-19 JN.1 vaccinations.
